Current Report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): June 9, 2010

HealthSouth Corporation

(Exact Name of Registrant as Specified in its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

001-10315	63-0860407
(Commission File Number)	(I.R.S. Employer Identification No.)

3660 Grandview Parkway, Suite 200, Birmingham, Alabama 35243

(Address of Principal Executive Officers, Including Zip Code)

(205) 967-7116

(Registrant’s telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. Regulation FD Disclosure .

HealthSouth Corporation (“HealthSouth” or the “Company”) will host an open house and presentation at its newly built 40-bed inpatient rehabilitation hospital in Loudoun County, Virginia on June 9, 2010. The Company will distribute to attendees a copy of the handout attached to this Current Report on Form 8-K as Exhibit 99.1. The handout addresses, among other things, the Company’s strategy, financial performance, and development process as well as information related to the new hospital, such as market dynamics and the clinical information system pilot project. The handout is available at http://investor.healthsouth.com by clicking on an available link.

In the handout attached to this Current Report on Form 8-K as Exhibit 99.1, the Company provides the following brief update on operational performance as of June 9, 2010:

Good performance through May

•

Volume : solid in April, softened in May, appears to be rebounding in June;

•

Expenses : continue to be aggressively managed; and

•

Pricing : favorable year-over-year trend.

In the handout, the Company also notes that it began integration of the newly acquired Desert Canyon Rehabilitation Hospital on June 1, 2010 and that the newly built hospital in Loudoun County will begin accepting patients in mid-June 2010.

The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The furnishing of this report is not intended to constitute a determination by the Company that the information is material or that the dissemination of the information is required by Regulation FD.

Note Regarding Presentation of Non-GAAP Financial Measures

The handout references the Company’s Adjusted Consolidated EBITDA, a non-GAAP financial measure. The Company continues to believe Adjusted Consolidated EBITDA as defined in its credit agreement is a measure of its ability to service its debt and its ability to make capital expenditures.

The Company uses Adjusted Consolidated EBITDA on a consolidated basis as a liquidity measure. The Company believes this financial measure on a consolidated basis is important in analyzing its liquidity because it is the key component of certain material covenants contained within the Company’s credit agreement, which is discussed in more detail in Note 8, Long-term Debt, to the consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2009 (the “2009 Form 10-K”). These covenants are material terms of the credit agreement, and the credit agreement represents a substantial portion of the Company’s capitalization. Non-compliance with these financial covenants under the credit agreement – its interest coverage ratio and its leverage ratio – could result in the Company’s lenders requiring the Company to immediately repay all amounts borrowed. If the Company anticipated a potential covenant violation, it would seek relief from its lenders, which would have some cost to the Company, and such relief might not be on terms favorable to those in the Company’s existing credit agreement. In addition, if the Company cannot satisfy these financial covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted Consolidated EBITDA is critical to the Company’s assessment of its liquidity.

In general terms, the definition of Adjusted Consolidated EBITDA, per the credit agreement, allows the Company to add back to or subtract from consolidated net income unusual non-cash or non-recurring items. These items include, but may not be limited to, (1) amounts associated with government, class action, and related settlements, (2) amounts related to discontinued operations and closed locations, (3) charges in respect of

professional fees for reconstruction and restatement of financial statements, including fees paid to outside professional firms for matters related to internal controls and legal fees for continued litigation and support matters discussed in Note 22, Settlements , and Note 23, Contingencies and Other Commitments , to the consolidated financial statements accompanying the 2009 Form 10-K and Note 8, Contingencies , to the condensed consolidated financial statements included in Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2010 (the “March 2010 Form 10-Q”), (4) stock-based compensation expense, (5) net investment and other income (including interest income), and (6) fees associated with the Company’s divestiture activities.

In accordance with the credit agreement, the Company is allowed to add certain other items to the calculation of Adjusted Consolidated EBITDA, and there may also be certain other deductions required. This includes the interest income associated with income tax recoveries, as discussed in Note 19, Income Taxes , to the consolidated financial statements included in the 2009 Form 10-K. In addition, the Company is allowed to add non-recurring cash gains, such as the cash proceeds from the UBS Settlement (see Note 22, Settlements , to the consolidated financial statements included in the 2009 Form 10-K) to the calculation of Adjusted Consolidated EBITDA. As these adjustments may not be indicative of the Company’s ongoing performance, they have been excluded from Adjusted Consolidated EBITDA presented herein and included in the handout attached as Exhibit 99.1.

However, Adjusted Consolidated EBITDA is not a measure of financial performance under generally accepted accounting principles in the United States of America (“GAAP”), and the items excluded from Adjusted Consolidated EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted Consolidated EBITDA should not be considered a substitute for net income or cash flows from operating, investing, or financing activities. The Company reconciles Adjusted Consolidated EBITDA to net income, which reconciliation is set forth in the handout attached as Exhibit 99.1, and to net cash provided by operating activities, which reconciliation is set forth below. Because Adjusted Consolidated EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted Consolidated EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in the 2009 Form 10-K.

Reconciliation of Net Cash Provided by Operating Activities to Adjusted Consolidated EBITDA

	Three Months Ended						Year Ended			Year Ended
	March 31,						December 31,			December 31,
	2010			2009			2009			2008

Net cash provided by operating activities	$	84.8		$	183.1		$	406.1		$	227.2
Provision for doubtful accounts		(6.9	)		(7.8	)		(33.1	)		(27.0	)
Professional fees-accounting, tax, and legal		2.9			4.8			8.8			44.4
Interest expense and amortization of debt
discounts and fees		30.5			34.4			125.8			159.5
UBS Settlement proceeds, gross		-			(100.0	)		(100.0	)		-
Equity in net income of nonconsolidated affiliates		2.6			2.5			4.6			10.6
Net income attributable to noncontrolling
interests in continuing operations		(9.8	)		(8.3	)		(33.4	)		(29.8	)
Amortization of debt discounts and fees		(1.7	)		(1.6	)		(6.6	)		(6.5	)
Distributions from nonconsolidated affiliates		(2.1	)		(1.5	)		(8.6	)		(10.9	)
Current portion of income tax expense (benefit)		2.1			(0.3	)		(7.3	)		(73.8	)
Change in assets and liabilities		0.7			(9.0	)		0.8			53.1
Change in government, class action, and
related settlements liability		0.8			1.7			11.2			7.4
Other operating cash used in (provided by)
discontinued operations		2.2			0.5			13.5			(11.4	)
Other		0.3			(0.1	)		1.2			(1.6	)
Adjusted Consolidated EBITDA	$	106.4		$	98.4		$	383.0		$	341.2

For the three months ended March 31, 2010, net cash used in investing activities was $26.2 million and resulted primarily from capital expenditures, net settlement payments related to interest rate swaps, and an increase in restricted cash offset by proceeds from the sale of a hospital in Baton Rouge, Louisiana. Net cash used in financing activities during the three months ended March 31, 2010 was $22.7 million and resulted primarily from distributions paid to noncontrolling interests of consolidated affiliates, dividends paid on the Company’s convertible perpetual preferred stock, and net debt payments.

For the three months ended March 31, 2009, net cash used in investing activities was $30.2 million and resulted primarily from capital expenditures and net settlement payments related to an interest rate swap. Net cash used in financing activities during the three months ended March 31, 2009 was $94.4 million and resulted primarily from net debt payments made during the period, as well as distributions paid to noncontrolling interests of consolidated affiliates and dividends paid on the Company’s convertible perpetual preferred stock.

For the year ended December 31, 2009, net cash used in investing activities was $133.0 million and resulted primarily from capital expenditures and net settlement payments related to interest rate swaps. Net cash used in financing activities during the year ended December 31, 2009 was $224.3 million and resulted primarily from net debt payments made during the period, as well as distributions paid to noncontrolling interests of consolidated affiliates, dividends paid on the Company’s convertible perpetual preferred stock, and debt amendment and issuance costs.

For the year ended December 31, 2008, net cash used in investing activities was $40.0 million and resulted primarily from capital expenditures, including expenditures associated with development activities, and net settlement payments related to an interest rate swap offset by proceeds from asset disposals, including the Company’s corporate campus. Net cash used in financing activities during the year ended December 31, 2008 was $176.0 million and resulted primarily from net debt payments made during the period, as well as distributions paid to noncontrolling interests of consolidated affiliates and dividends paid on the Company’s perpetual preferred stock, offset by proceeds from the issuance of common stock.

Forward-Looking Statements

The information contained in this Current Report on Form 8-K and the handout attached as Exhibit 99.1 includes certain estimates, projections, and other forward-looking information that reflect the Company’s current views with respect to future events and financial performance. These estimates, projections, and other forward-looking information are based on assumptions the Company believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual results, and those differences may be material.

There can be no assurance that any estimates, projections, or forward-looking information will be realized. All such estimates, projections, and forward-looking information speak only as of the date hereof. The Company undertakes no duty to publicly update or revise the information contained herein or in the handout.

You are cautioned not to place undue reliance on the estimates, projections, and other forward-looking information in this Current Report on Form 8-K or the handout as they are based on current expectations and general assumptions and are subject to various risks, uncertainties, and other factors, including those set forth in the 2009 Form 10-K, the March 2010 Form 10-Q, and other documents the Company previously filed with the SEC, many of which are beyond the Company’s control. These factors may cause actual results to differ materially from the views, beliefs and estimates expressed herein.

ITEM 9.01. Financial Statements and Exhibits

(d) Exhibits

99.1

Handout of HealthSouth Corporation used in connection with the June 9, 2010 open house and presentation at its new inpatient rehabilitation hospital in Loudoun County, Virginia.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

	HEALTHSOUTH Corporation

	By:	/s/ D OUGLAS E. C OLTHARP
		Name: Douglas E. Coltharp
		Title: Executive Vice President and Chief Financial Officer

Dated: June 9, 2010

HealthSouth Rehabilitation
Hospital of Northern Virginia

June 9, 2010

Exhibit 99.1

Note Regarding Forward-Looking Statements
The information contained in this presentation includes certain estimates, projections and other forward-looking information
that reflect our current views with respect to future events and financial performance. These estimates, projections and other
forward-looking information are based on assumptions that HealthSouth believes, as of the date hereof, are reasonable.
Inevitably, there will be differences between such estimates and actual results, and those differences may be material.

There can be no assurance that any estimates, projections or forward-looking information will be realized. All such estimates,
projections and forward-looking information speak only as of the date hereof. HealthSouth undertakes no duty to publicly
update or revise the information contained herein.

You are cautioned not to place undue reliance on the estimates, projections and other forward-looking information in this
presentation as they are based on current expectations and general assumptions and are subject to various risks,
uncertainties and other factors, including those set forth in our Form 10-K for the year ended December 31, 2009, and our
Form 10-Q for the quarter ended March 31, 2010, and in other documents we previously filed with the SEC, many of which
are beyond our control, that may cause actual results to differ materially from the views, beliefs and estimates expressed
herein.

Note Regarding Presentation of Non-GAAP Financial Measures
The following presentation includes certain “non-GAAP financial measures” as defined in Regulation G under the Securities
Exchange Act of 1934. The Appendix at the end of this presentation includes reconciliations of the non-GAAP financial
measures found in the following presentation to the most directly comparable financial measures calculated and presented in
accordance with Generally Accepted Accounting Principles in the United States. Our Form 8-K, dated June 9, 2010, provides
further explanation and disclosure regarding our use of non-GAAP financial measures and should be read in conjunction with
these presentation slides.

Cautionary Statements

Exhibit 99.1

Agenda

1:00 p.m.

2:00 p.m.

2:30 p.m.

3:00 p.m.

Overview, Strategy and Performance Update

Development Process, De novo Trends and

Market Dynamics for Loudoun County

Clinical Information System

Tour

Group 1 (Christina Stover, Mark Tarr, Dayle Unger)

Group 2 (Jeff Ruskan, Jay Grinney, Randy Carpenter)

Group 3 (Terry Maxhimer, Doug Coltharp, Rusty Yeager)

Wrap-up and Q&A

Transportation to Dulles Airport

Jay Grinney

Mark Tarr

Randy Carpenter

Exhibit 99.1

• Reminder : Based on the results of Q1, the Company raised its 2010
full-year performance forecast to the high end of the guidance ranges.

• Good performance through May (volume, expense management and
pricing).

§ Volume: solid in April, soft in May, appears to be rebounding in June

§ Expenses: continue to be aggressively managed

§ Pricing: favorable year-over-year trend

• New Hospitals:

§ Began integration of Desert Canyon Rehabilitation Hospital on June 1, 2010

§ Will begin taking patients mid-June at HealthSouth Rehabilitation Hospital
of Northern Virginia

• As is our policy, full-year guidance will be addressed as part of our
quarterly earnings release.

Operating Performance Update

Exhibit 99.1

Strategy Recap

ü Priority : Reduce our leverage and strengthen our balance sheet

- No obvious near-term debt repayment opportunities

- 10 ¾ Senior Notes callable June 2011 at 105 ⅜

- 2010 focus: growing Adjusted Consolidated EBITDA (1) to reduce leverage

ü Near-term : Capitalize on our market-leading position in inpatient
rehabilitation

- Continue to increase market share

- Break ground on a minimum of two new rehabilitation hospitals each year

- Acquire or joint venture a minimum of two IRFs per year

ü Longer-term : Prepare for potential expansion into complementary
post-acute segments

(1) Reconciliation to GAAP provided on slides 30 and 31.

Exhibit 99.1

Agenda

1:00 p.m .

2:00 p.m.

2:30 p.m.

3:00 p.m.

Overview, Strategy and Performance Update

Development Process, De novo Trends and

Market Dynamics for Loudoun County

Clinical Information System

Tour

Group 1 (Christina Stover, Mark Tarr, Dayle Unger)

Group 2 (Jeff Ruskan, Jay Grinney, Randy Carpenter)

Group 3 (Terry Maxhimer, Doug Coltharp, Rusty Yeager)

Wrap-up and Q&A

Transportation to Dulles Airport

Jay Grinney

Mark Tarr

Randy Carpenter

Exhibit 99.1

• Population and
Demographics

• Acute Care Referral
Sources

• Inpatient Rehab
Competition

• SNF Presence

• Payer Environment

• CON/Non-CON

National Market
Assessment

( 3,141 Counties in 48
states studied)

Target
Opportunity

List

( 160 Opportunities
Identified )

Existing IRF
Assessment

Corporate
Priority
Assessment

Active
Development
List

Market Assessment Process

Strategic
Approach

• Build

• Buy

• JV

Regional
President
Assessment

Exhibit 99.1

De Novo Evaluation Process

CON
Approval

Site
Selection

Cost
Assessment

Proforma
Financials

Execution

• Permitting

• Contract for land

Exhibit 99.1

Proforma 40 Bed De Novo

Target Cash Pay-back 6-7 years

Exhibit 99.1

HealthSouth Rehabilitation Hospital of Northern
Virginia Market Dynamics

ü COPN (certificate of public
need) state

ü Five acute care hospitals
without rehab within a 30
minute drive time

ü Low penetration of skilled
nursing facilities

ü Rehab CAGR above U.S.
average

ü Below U.S. average
unemployment rate

Exhibit 99.1

Agenda

1:00 p.m.

2:00 p.m.

2:30 p.m.

3:00 p.m .

Overview, Strategy and Performance Update

Development Process, De novo Trends and

Market Dynamics for Loudoun County

Clinical Information System

Tour

Group 1 (Christina Stover, Mark Tarr, Dayle Unger)

Group 2 (Jeff Ruskan, Jay Grinney, Randy Carpenter)

Group 3 (Terry Maxhimer, Doug Coltharp, Rusty Yeager)

Wrap-up and Q&A

Transportation to Dulles Airport

Jay Grinney

Mark Tarr

Randy Carpenter

Exhibit 99.1

Clinical Information Systems in Healthcare

The Facts

Ø Clinical information systems (CIS) are a key component of successful
quality, safety and patient satisfaction initiatives in healthcare

Ø Hospitals that implemented Computerized Physician Order Entry
(CPOE) reported better quality of care and lower mortality rates
according to a recent study*

Ø 2008 100 Most Wired Hospitals achieved significantly better quality
indicators than other hospitals**

- Mortality rate

- Patient safety index

- Core measures index

Ø CIS adoption is not solely responsible for these results

Ø HOWEVER…adoption of CIS in healthcare is very slow!

* Source : Joint Commission Journal on Quality and Patient Safety, June 2008

** Source : The 100 Most Wired Hospitals and Health Systems 2008, Hospitals and Health Networks, July 2008

Exhibit 99.1

Source : HIMSS Analytics TM Database N = 5,235

Stage 2

Clinical Data Repository, Controlled Medical Vocabulary,

may have Document Imaging; Health Info Exchange capable

Stage 3

Nursing/clinical documentation , Clinical Decision Support(error check),

Digital Radiology

Stage 4

Computerized Physician Order Enter,

Clinical Decision Support (clinical protocols)

Stage 5

Closed loop medication administration, 5 rights with bar code

Stage 6

Physician documentation (structured templates), full Clinical

Decision Support (variance & compliance), full Digital Imaging

Stage 7

Complete EMR; standardized transactions to share data; Data

warehousing; Data continuity with Emergency Dept, ambulatory

Stage 1

Ancillaries - Lab, Radiology, Pharmacy - All Installed

Stage 0

All Three Ancillaries - Lab, Radiology, Pharmacy Not Installed

2005

0.0%

.001%

2.5%

10.0%

48.8%

19.6%

18.4%

0.7%

1.6%

3.8%

7.4%

50.9%

16.9%

7.2%

2009

Final

11.5%

2005-2009 EMR Adoption Model Trends
(5,235 non-federal acute care U.S. hospitals)

Exhibit 99.1

Electronic Medical Record (EMR) Adoption Model

Ø Most U.S. hospitals are at Stage 3 (Foundation Stage) or below

Ø Stages 0, 1 and 2 are slowing

Ø Stage 3 is growing the fastest

- 10% in 2005 - 50.9% in 2009

Ø Advanced Stages 3 through 7

- Require only one service or unit to be implemented

- Reduce medical errors and improve clinical outcomes

Ø Stage 5 is the most difficult to achieve

- Integration, technology and reengineering requirements

- Significant investment in capital, executive commitment and culture adoption

Ø Over 86% of U.S. Hospitals do NOT have CPOE (computerized
physician order entry) implemented

Exhibit 99.1

HealthSouth Clinical Information Technology
Current State

Item	Current State	Comments
Clinical Documentation	Mostly manual	Some MS Word templates
Order Management	Manual	Team working on automation with pilot in multiple hospitals.
Pharmacy	Automated	All HealthSouth IRFs, primary product is lacking functionality.
Lab/Radiology Imaging	N/A	In house not required in most hospitals
Document Management	Basic	Business office imaging capabilities exist
Clinical Outcomes	Mostly manual	Clinical data repository not available

Exhibit 99.1

Vendor Selection Process

– 2005 - Request for Proposal (13 vendors responded; 3 finalists)

– 2007 Project on hold due to business unit divestitures

– 2009 Cerner final selection

– July 2009 Core team assembled

– Integrated solution meeting all functional requirements

– Enterprise capable vendor with scalability

– Positive references

– Experience in inpatient rehabilitation setting

Exhibit 99.1

Key Features

Patient Safety Features:		Operational Efficiency:
Focused online documentation (physician, nursing, therapy)		Point of care charge capture (therapy intensity)
Real time patient condition awareness (medical and functional) from any team member support device		Results reporting feeds from legacy and outside systems
Clinical data repository (reporting and outcomes)		Workflow management
Electronic Medical Record		Patient/resource scheduling
Medication administration system with Point of Care bar-coding		Knowledge content/patient education
Computerized physician order entry with clinical decision support alerts (Dec 2010)

Exhibit 99.1

2
2

Project Timeline

Clinical

Visioning

2005

Vendor

Evaluations

2006

Project On Hold

(Divestitures)

2007

Project Restart &

Vendor

Re-evaluations

2008

Cerner

Selected

Feb
2009

Pilot Contract

Negotiation

Jun 2009

Pilot Project

Kickoff

Aug 2009

Benefits

Recognition

Study

Jul - Dec 2010

Pilot

“Go-Live”

Jun 2010

Executive/

Board Review

Feb 2011

Enterprise
Contract
Negotiation

Mar - Jun 2011

Exhibit 99.1

Agenda

1:00 p.m.

2:00 p.m.

2:30 p.m.

3:00 p.m.

Overview, Strategy and Performance Update

Development Process, De novo Trends and

Market Dynamics for Loudoun County

Clinical Information System

Tour

Group 1 (Christina Stover, Mark Tarr, Dayle Unger)

Group 2 (Jeff Ruskan, Jay Grinney, Randy Carpenter)

Group 3 (Terry Maxhimer, Doug Coltharp, Rusty Yeager)

Wrap-up and Q&A

Transportation to Dulles Airport

Jay Grinney

Mark Tarr

Randy Carpenter

Exhibit 99.1

Appendix

Exhibit 99.1

HealthSouth Rehabilitation Hospital of Northern
Virginia

• Grand Opening June 2010

• 40 private beds with flat screen televisions and wireless internet capability

• 47,500 square feet

• Expected to generate approximately 80 new, full-time jobs

• Latest rehabilitation equipment and therapy tools

• Point of care documentation using a clinical information system

• Serve patients throughout the Northern Virginia area

• Area’s newest free-standing inpatient rehabilitation hospital

Exhibit 99.1

Our Rehabilitation Disciplines

Rehabilitation physician : Daily visits by a physician trained in physical
medicine and rehabilitation.

Rehabilitation nursing : Implement each patient’s medical care program
as directed by his or her physician.

Physical therapy : Evaluate and design a treatment program to address
limitations in physical function, mobility and safety.

Occupational therapy : Design and deliver activity-based therapy to
promote independence in the areas of self care, home management and
community reintegration.

Respiratory therapy : Ensure proper respiratory function through
services such as oxygen supplements and aerosol treatments.

Exhibit 99.1

Our Rehabilitation Disciplines (cont’d)

Speech-language pathology : Assess and treat individuals with
communication and comprehension disorders, cognitive difficulties and
swallowing disorders.

Dietary and nutritional counseling : Supervise all meals to ensure
patients receive the necessary nutrition.

Case Management : Coordinate with the physician to ensure the patient’s
needs are met and involve the family and other caregivers in the patient’s
rehabilitation.

Post-discharge services : Complete the continuum of care with
outpatient therapy and home health.

Exhibit 99.1

State-of-the-art rehabilitation technologies :

VitalStim

VitalStim® Therapy is an
innovative procedure that
facilitates retraining of
throat muscles affected by
dysphagia, or difficulty
swallowing.

Reo Go

The Reo Go™ provides a
platform for robot-assisted
therapy that retrains arm
movements for patients
recovering from stroke or
other neurological conditions.

Experia
VitalStim with Biofeedback

Bioness NESS H200

The innovative NESS
H200 Neuroprosthetic and
Rehabilitation System from
Bioness Inc., helps
patients improve hand
function and voluntary
movement, helping them
return to daily activities
with confidence.

Exhibit 99.1

State-of-the-art rehabilitation technologies :

AutoAmbulator
Bringing cutting-edge
technology into the
rehabilitation process, the
AutoAmbulator is an innovative
therapeutic device designed to
help rehabilitate patients who
experience difficulty walking.

LiteGait

Ambulation training device - used
with and without a treadmill.

Exhibit 99.1

Reconciliation of Net Income to Adjusted Income from Continuing
Operations and Adjusted Consolidated EBITDA (1) (3) (4)

Exhibit 99.1

Reconciliation Notes

1. Adjusted income from continuing operations and Adjusted Consolidated EBITDA are
non-GAAP financial measures. The Company’s leverage ratio (Total Consolidated Debt
to Adjusted Consolidated EBITDA for the trailing four quarters) is, likewise, a non-GAAP
financial measure. Management and some members of the investment community utilize
adjusted income from continuing operations as a financial measure and Adjusted
Consolidated EBITDA and leverage ratio as liquidity measures on an ongoing basis.
These measures are not recognized in accordance with GAAP and should not be viewed
as an alternative to GAAP measures of performance or liquidity. In evaluating these
adjusted measures, the reader should be aware that in the future HealthSouth may incur
expenses similar to the adjustments set forth above.

2. Per share amounts for each period presented are based on basic weighted average
common shares outstanding for all amounts except adjusted income from continuing
operations per diluted share, which is based on diluted weighted average shares
outstanding. The difference in shares between the basic and diluted shares outstanding
is primarily related to our convertible perpetual preferred stock.

3. Adjusted income from continuing operations per diluted share and Adjusted Consolidated
EBITDA are two components of our guidance.

4. The Company’s Credit Agreement allows certain other items to be added to arrive at
Adjusted Consolidated EBITDA, and there may be certain other deductions required.